Figure 2

3-aminopyridine-2-carboxyaldehyde-thiosemicarbazone (3-AP) protracts resolution of γH2AX foci. Panel A: Manual counts (mean ± standard error) of retained γH2AX foci at 24 hours post therapy (i.e., start of cisplatin exposure) are depicted for SKOV3 and OVCAR3 treated cells. Cisplatin damages DNA resulting in visible γH2AX foci [19]. Cisplatin plus 3-AP treated cells demonstrated an increased number of γH2AX foci, compared to cisplatin alone (P < 0.001, star) or 3-AP preceding cisplatin (P < 0.001, star) treatment, indicative of retained cisplatin-mediated DNA damage.